Cargando…
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In th...
Autores principales: | Roulin, Didier, Cerantola, Yannick, Dormond-Meuwly, Anne, Demartines, Nicolas, Dormond, Olivier |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850884/ https://www.ncbi.nlm.nih.gov/pubmed/20226010 http://dx.doi.org/10.1186/1476-4598-9-57 |
Ejemplares similares
-
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
por: Blaser, Benjamin, et al.
Publicado: (2012) -
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011) -
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
por: Faes, Seraina, et al.
Publicado: (2017) -
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
por: Dufour, Marc, et al.
Publicado: (2011) -
Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
por: Faes, Seraina, et al.
Publicado: (2016)